Clinical trials: Cancer Colon
Colorectal Neoplasms
Evaluation of Some Risk Factors Associated With Colorectal Cancer
1. Evaluation of some risk factors (e.g. smoking, heavy metal exposure, and organophosphorus exposure) on CRC. 2. Estimation of KRAS and BRAF genes mutations associated with CRC. 3.
- Trial name
- NCT05170360
- Testing
- Assessment of smoking ,heavy metal, organophosphorus exposure and d) Mutational analysis of the KRAS and BRAF genes:
- Volunteers
- 100 people
- Sponsor
- Assiut University
Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer
This phase I trial studies the side effects and the best dose of irinotecan hydrochloride, based on a genetic test, when given in combination with fluorouracil, leucovorin calcium, and cetuximab as first-line therapy in treating…
- Trial name
- NCT02573220
- Testing
- Cetuximab, Fluorouracil, Irinotecan Hydrochloride
- Where
- Italy
- Sponsor
- University of Chicago
Circulating Markers, Metastatic Colorectal Cancer
Correlation Between Circulating Tumour Markers Early Variations and Clinical Response in First Line Treatment of Metastatic Colorectal Cancer
The chemotherapy monitoring is currently based on radiological (RECIST 1.1 guideline) and clinical evaluation every 3 months. Circulating markers as Carcino Embryonic Antigen (CEA), circulating tumour DNA and total cell free DNA…
- Trial name
- COCA-MACS (NCT02872779)
- Testing
- Blood sampling for free mutant DNA analysis
- Where
- France
- Volunteers
- 74 people
- Sponsor
- University Hospital, Rouen
Colorectal Cancer (CRC)
A Phase II Study of Pirfenidone Plus PD-1 Inhibitor With or Without Hypofractionated Radiotherapy for Refractory pMMR/MSS Colorectal Cancer
This study aims to evaluate the safety, tolerability, and efficacy of pirfenidone and PD-1 monoclonal antibody combined with or without hypofractionated radiotherapy in the treatment of advanced refractory pMMR/MSS colorectal…
- Trial name
- NCT07644286
- Testing
- Pirfenidone in combination with a PD-1 inhibitor, hypofractionated radiotherapy
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Tao Zhang
Lynch Syndrome I (Site-specific Colonic Cancer)
Finding the Best Dose of Aspirin to Prevent Lynch Syndrome Cancers
A randomised double blind dose non-inferiority trial of a daily dose of 600mg versus 300mg versus 100mg of enteric coated aspirin as a cancer preventive in carriers of a germline pathological mismatch repair gene defect, Lynch…
- Trial name
- CaPP3 Israel (NCT02497820)
- Testing
- Aspirin
- Where
- Israel
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Colon Neoplasm
Calculating of Correlations Between ADR, PDR, MAP
The aim of our study is to compare MAP (mean adenoma per colonoscopy) with ADR (adenoma detection rate) and PDR (polyp detection rate) of all colonoscopists in our department
- Trial name
- NCT03723720
- Testing
- Colonoscopy
- Where
- Czechia
- Volunteers
- 6,925 people
- Sponsor
- Hospital Frydek-Mistek
Colorectal Neoplasms, Metastatic Disease
Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer
The purpose of this study is to assess the efficacy and safety of single-agent regorafenib in the first line treatment of frail and/or unfit for polychemotherapy patients with metastatic colorectal cancer (mCRC)
- Trial name
- REFRAME (NCT01875380)
- Testing
- Regorafenib
- Where
- Spain
- Volunteers
- 46 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Colorectal Neoplasms, Anal, Colon, and Rectal Cancers
Feasibility of Autologous Tumor Cell-TLR9 Agonist Vaccination for Metastatic Colorectal Cancer
Current therapies for metastatic colorectal cancer only prolong life for approximately 2 years. A more innovative therapy that prolongs life significantly or even cures is needed.
- Trial name
- NCT00780988
- Testing
- Autologous tumor cell + CpG vaccine, Autologous hematopoietic and immune cell rescue (transplantation)
- Where
- United States
- Sponsor
- Stanford University
Endoscopy, Colonoscopy
Retrospective Review of Gastrointestinal System Endoscopy Procedures
The aim of the study is retrospectively evaluating all features of endoscopic and pathological diagnoses of cases who underwent upper and lower gastrointestinal endoscopy.
- Conditions
- Endoscopy, Colonoscopy, Gastroscopy, Colonic Polyps
- Trial name
- RRGIE (NCT05012527)
- Where
- Turkey (Türkiye)
- Volunteers
- 15,448 people
- Sponsor
- Istanbul Sultanbeyli State Hospital
Metastatic Colorectal Cancer
Safety and Efficacy Study of Panitumumab+Irinotecan in Patients Wild-Type (WT) KRAS Metastatic Colorectal Cancer Refractory to Irinotecan Based Chemotherapy (SPECTRA)
The purpose of the study is to evaluate the efficacy and safety of the combination of Panitumumab with Irinotecan in patients with Wild-Type KRAS metastatic colorectal cancer refractory to irinotecan based chemotherapy.
- Trial name
- SPECTRA (NCT00958386)
- Testing
- Panitumumab+irinotecan
- Where
- Spain
- Volunteers
- 61 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Pseudomyxoma Peritonei, Colorectal Cancer
HIPEC Using High Intra-abdominal Pressure
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is a promising therapy for peritoneal carcinomatosis (PC) of various origins.
- Trial name
- HIPEC-IAP (NCT02949791)
- Testing
- Cytoreductive surgery, Low Intra abdominal pressure HIPEC, High Intra abdominal pressure HIPEC
- Where
- Italy
- Volunteers
- 38 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Metastatic Malignant Neoplasm in the Brain, Metastatic Solid Neoplasm
APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of APN401 in treating patients with pancreatic cancer, colorectal cancer, or other solid tumors that have spread to other places in the body or have come back.
- Conditions
- Metastatic Malignant Neoplasm in the Brain, Metastatic Solid Neoplasm, Recurrent Colorectal Carcinoma, Recurrent Pancreatic Carcinoma
- Trial name
- NCT03087591
- Testing
- Laboratory Biomarker Analysis, siRNA-transfected Peripheral Blood Mononuclear Cells (PBMC) APN401
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Wake Forest University Health Sciences
Colorectal Cancer (CRC)
Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treatment of Advanced Colorectal Cancer: A Single-arm, Phase II Clinical Study
This is an investigator-initiated, prospective, multicenter, single-arm phase II clinical study. It aims to evaluate the efficacy and safety of fractionated liposomal irinotecan (II)-based combination chemotherapy (FOLFIRInali-3)…
- Trial name
- NCT07047560
- Testing
- fractionated liposomal irinotecan (II)-based combination chemotherapy (FOLFIRInali-3) plus bevacizumab (Bev)
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Colorectal Cancer
Study of Association Between Peripheral Immune Cells and Recurrence in Stage II/III Colorectal Cancer
The purpose of this study is to determine association between Peripheral Immune Cells(PIC) and recurrence in stage II/III colorectal cancer
- Trial name
- PICC-1 (NCT01911988)
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Colorectal Cancer, Precancerous Condition
Improving the Frequency of Colonoscopy in Patients With a Previous Colorectal Polyp
RATIONALE: Receiving a reminder letter from their doctor may increase the frequency of colonoscopy in patients who have had a colorectal polyp removed.
- Trial name
- NCT00397969
- Testing
- counseling intervention, screening colonoscopy
- Where
- 2 sites in United States
- Volunteers
- 800 people
- Sponsor
- Harvard Medical School (HMS and HSDM)
Colorectal Cancer, Neoadjuvant Therapy
Apatinib Treatment as the Neoadjuvant Therapy in Advanced Colorectal Cancer
Apatinib has been proved to be effective and safe among patients in advanced colorectal cancer in several trials. the investigators aimed to evaluate its efficacy and safety as the neoadjuvant therapy in real world practice, and…
- Trial name
- NCT03377842
- Testing
- FOLFOX regimen, apatinib and FOLFOX regimen
- Volunteers
- 100 people
- Sponsor
- Sichuan Provincial People's Hospital
Colorectal Cancer
A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer
The purpose of this study is to determine whether lenalidomide in combination with cetuximab is safe and effective in patients with KRAS mutant colorectal cancer.
- Trial name
- NCT01032291
- Testing
- cetuximab, lenalidomide
- Where
- 17 sites in Australia, Belgium and 4 more
- Volunteers
- 51 people
- Sponsor
- Celgene Corporation
Colorectal Cancer
ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer
This is a Phase 1b open-label, multiple dose/schedule sequential study to determine the safety and efficacy of the oxidative phosphorylation (OxPhos) pathway inhibitor ME-344 in combination with bevacizumab in subjects with…
- Trial name
- NCT05824559
- Testing
- ME-344, Bevacizumab
- Where
- 7 sites in United States
- Volunteers
- 23 people
- Sponsor
- MEI Pharma, Inc.
Colorectal Cancer
Ancillary Study of Methylation Biomarkers in a Randomized Controlled Trial of a Personalized Prevention of Colorectal Cancer
Based on the magnesium tolerance test (MTT, "gold standard" for assessing magnesium (Mg) status), it was found that over 50% of participants in the US exhibited Mg deficiency.
- Trial name
- NCT04196803
- Testing
- Magnesium glycinate
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Non-Small Cell Lung Cancer
Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer
The main purpose of this study is to evaluate the best dose, safety and side effects of ridaforolimus when given with cetuximab for patients with head and neck, lung and colon cancer that has progressed after initial therapy.
- Trial name
- NCT01212627
- Testing
- Ridaforolimus
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Angela Taber MD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.